Ron Mayron Net Worth

The estimated Net Worth of Ron Mayron is at least $12.5 Thousand dollars as of 18 January 2022. Ron Mayron owns over 7,000 units of Entera Bio Ltd stock worth over $12,460 and over the last 3 years Ron sold ENTX stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Ron Mayron ENTX stock SEC Form 4 insiders trading

Ron has made over 1 trades of the Entera Bio Ltd stock since 2022, according to the Form 4 filled with the SEC. Most recently Ron bought 7,000 units of ENTX stock worth $19,600 on 18 January 2022.

The largest trade Ron's ever made was buying 7,000 units of Entera Bio Ltd stock on 18 January 2022 worth over $19,600. On average, Ron trades about 1,750 units every 0 days since 2022. As of 18 January 2022 Ron still owns at least 7,000 units of Entera Bio Ltd stock.

You can see the complete history of Ron Mayron stock trades at the bottom of the page.

What's Ron Mayron's mailing address?

Ron's mailing address filed with the SEC is KIRYAT HADASSAH,, MINRAV BUILDING, 5TH FLOOR, JERUSALEM, L3, 9112002.

Insiders trading at Entera Bio Ltd

Over the last 3 years, insiders at Entera Bio Ltd have traded over $0 worth of Entera Bio Ltd stock and bought 467,822 units worth $484,536 . The most active insiders traders include Gerald M Lieberman, Miranda Jayne Toledano, and Sean Ellis. On average, Entera Bio Ltd executives and independent directors trade stock every 32 days with the average trade being worth of $36,205. The most recent stock trade was executed by Haya Taitel on 12 January 2024, trading 9,500 units of ENTX stock currently worth $9,405.

What does Entera Bio Ltd do?

entera bio ltd. is a biotechnology company located in israel.

Complete history of Ron Mayron stock trades at Entera Bio Ltd

Entera Bio Ltd executives and stock owners

Entera Bio Ltd executives and other stock owners filed with the SEC include:

• Phillip Schwartz,
  President of Research and Development
• Gerald Lieberman,
  Independent Chairman of the Board
• Arthur Santora,
  Chief Medical Officer
• Dr. Phillip Schwartz Ph.D.,
  Exec. VP, Pres of R&D and Director
• Roger Garceau,
  Chief Executive Officer, Director
• Hillel Galitzer,
  Chief Operating Officer
• Dr. Hillel Galitzer,
  Chief Operating Officer
• Dr. Arthur C. Santora II, M.D., Ph.D.,
  Chief Medical Officer
• Kiryat Hadassah,
  IR Contact Officer
• Miranda Toledano,
  Independent Director
• Gerald Ostrov,
  Independent Director
• Faith Charles,
  Independent Director
• Yonatan Malca,
  Director
• Sean Ellis,
  Director
• Zeev Bronfeld,
  Director
• Jonathan Lieber,
  Chief Financial Officer - U.S.-based
• Dana Yaacov-Garbeli,
  Chief Financial Officer
• Dr. Roger J. Garceau,
  Chief Devel. Advisor & Director
• Ramesh Ratan,
  U.S. Chief Financial Officer
• Dana Yaacov-Garbeli CPA,
  Chief Financial Officer
• Dr. Spiros Jamas,
  CEO & Director
• Haya Taitel,
  Director
• Ramesh Ratan,
  U.S.based CFO
• Spiros Jamas,
  Chief Executive Officer
• Ron Mayron,
  Director